#United States #Palo Alto #Glooko #Hedia #DiabetesManagement

Hedia and Glooko Join Forces to Improve Diabetes Management

In a major development for diabetes care, Glooko, Inc. and Hedia have unveiled an innovative interoperable solution aimed at enhancing the management of diabetes through personalized bolus insulin dosing. This new collaboration merges connected care, remote patient monitoring, and advanced digital therapeutic technologies, ensuring that individuals living with Type 1 and Type 2 diabetes receive the precise support they need in their daily routines.

A New Era in Diabetes Management

The launch, which is initially available in the United Kingdom, will soon expand to other European markets, symbolizing a significant step forward in diabetes management. For those unfamiliar with the term, a bolus refers to the additional insulin needed to manage expected spikes in blood glucose levels, typically related to meals or snacks. Calculating the correct bolus dosage can be a challenging task for many diabetes patients and their healthcare providers, often leading to inconsistencies in blood sugar levels.

Through Glooko's advanced platform, patients are enabled to conveniently share vital diabetes-related data with their healthcare professionals. The data shared can include important metrics such as blood glucose levels, insulin doses, carbohydrate intake, exercise activity, blood pressure, and weight. By integrating the Hedia Diabetes Assistant with Glooko's platform, patients receive personalized recommendations for their insulin dosage, making diabetes management smoother and more effective, while simultaneously supporting stable blood glucose levels.

Enhanced Insights for Healthcare Providers

Healthcare providers are not left behind in this innovative collaboration. They gain improved visibility and access to their patients’ health data, empowering them to deliver more effective care. This cohesive approach to managing multiple daily insulin injections helps streamline the process and fosters better outcomes for both patients and providers. The efficiencies gained from this collaboration are particularly significant for those in remote care settings or in-person service environments.

“We are thrilled to introduce this algorithm-driven, personalized diabetes solution to our patients and their healthcare teams,” stated Mike Alvarez, CEO of Glooko. “Our partnership with Hedia is underpinned by extensive clinical data that validates Hedia's approach, and our joint efforts ensure that even those who cannot access traditional insulin pumps are afforded the support they need for effective diabetes management.”

Lars Christian Lund, CEO of Hedia, echoed the sentiment, stating, “Collaborating with Glooko, a leading player in digital health, aligns perfectly with our mission to enhance the quality of life for individuals with diabetes. One of our principal considerations in developing our technology has been regulatory compliance, and we are proud to confirm that our platform is MDR certified in Europe. This certification ensures that patients and their healthcare teams are utilizing the best solutions available.”

About Hedia and Glooko

Hedia is paving the way as a top digital therapeutics company focused on diabetes care. Their mission is to empower individuals dependent on insulin to gain better control over their condition, thereby improving the quality of life for diabetes patients. The Hedia Diabetes Assistant is designed to account for personal habits and individual needs, delivering tailored insulin recommendations based on user data such as blood glucose readings, active insulin tracking, carbohydrate measurement, and physical activity monitoring.

Glooko complements this with its commitment to boosting health outcomes for individuals managing chronic conditions. The company provides a tailored, connected care platform designed to enhance communication between patients and their healthcare providers, facilitating greater patient engagement and adherence through innovative digital therapeutic solutions. With Glooko's technologies deployed across more than 30 countries and over 10,000 clinical locations, the platform has made a difference for over 4.4 million users worldwide.

Conclusion

This groundbreaking partnership between Hedia and Glooko signifies a paradigm shift in diabetes management by facilitating personalized insulin dosing tailored to individual needs. The seamless combination of technology and healthcare expertise aims not only to improve patient outcomes but to redefine the landscape of diabetes care for the future. For more information about this innovative solution, you can visit Glooko's official website.